about
Role of Viral miRNAs and Epigenetic Modifications in Epstein-Barr Virus-Associated Gastric CarcinogenesisRole of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular CarcinomaTriple negative breast cancer: looking for the missing link between biology and treatmentsAn adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.Regulated and Liver-Specific Tamarin Alpha Interferon Gene Delivery by a Helper-Dependent Adenoviral VectorStructural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusionRole of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewEfficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNAStructural characterization of a biologically active human lipocortin 1 expressed in Escherichia coliCCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomySpheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftmentAnti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways.Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis.Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.Formation of the 3' end on U snRNAs requires at least three sequence elements.Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver.A novel method for site-directed mutagenesis: its application to an eukaryotic tRNAPro gene promoterAbscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.Inhibition of eukaryotic tRNA transcription by potential Z-DNA sequences.IL-6 is required for airway mucus production induced by inhaled fungal allergensQuantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.A novel minigene scaffold for therapeutic cancer vaccinesRole of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.MMP11: a novel target antigen for cancer immunotherapy.Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.Transcription of multimeric tRNA genes.Gene therapy progress and prospects: transcription regulatory systems.Functional assay of tRNA molecules transcribed from a purified gene.Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control studySuperior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen.An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirusIdentification of sequences responsible for acute-phase induction of human C-reactive protein.
P50
Q26765643-80104B55-235F-4CB1-B502-D8B895E28831Q26778413-034F23CA-9195-44F2-A126-A99CDCBE9712Q26783122-9F2768DC-A3F3-40A2-B48D-526E8273E47DQ27469506-D6013860-F4AE-4E45-83E5-C34BF14C17B3Q27469612-A3C29B9A-B040-4626-9D2C-EA54D3CFC8B8Q27641682-2C4A8B10-9F35-45CB-8555-C9E12D689447Q28069963-558C275F-74FE-45B1-B7E6-F6AE2581059BQ28251922-836DFCB1-12F6-4A5A-AB2F-D396D5F77CD4Q28265578-06849FEC-9A49-4638-81B3-F305E88F0C23Q28584735-54FF3910-43AB-4D35-A9FB-2884C6ADA460Q28742459-60B8D899-5322-412C-AB63-5509FCEBEC29Q33529392-ACAE5E1D-0DAC-4743-9714-1F6025219D25Q33550600-83806340-D5D3-48DF-869D-BF003D16A572Q33683537-627E75B6-28FD-4F4E-A288-087180F6AD8DQ33804926-9454F5AC-AA7F-4F33-9827-E16AA96D06ACQ33843078-27E4F132-4953-46F1-89EC-B77159F18E2AQ33880741-C4FC2385-624B-4143-AF8E-803EB1C5A243Q33889571-D095CA5D-1F35-474B-9CA7-139FAEB56B12Q33927932-5987EC1D-CF93-4E50-9341-B72EFAA63727Q33930593-457B6A9B-B852-42D5-BF15-42AEB20CE724Q33939674-E3EDDF6A-047A-46B4-8C16-51D90CBC91CBQ34089540-2E6D9005-CABE-48A8-8A07-ABA32FADC486Q34205196-D81BFEFB-8B89-4CE0-8A3D-8A5F1E9B82ACQ34283295-888AB31B-AEDB-4566-AA53-B6583F4ADD64Q34418540-B8E8E532-460C-4AA3-94DC-ED7BF5BFB3DEQ34419957-4F0263AF-DDFC-4EC7-A9A1-D65337811B07Q34433467-F41A7B95-B470-4C31-A541-DD1470382724Q34515007-FECE570E-9FC9-4864-A67C-17D07596DAF0Q34518350-6672EE8D-4927-498D-B9FD-4D4825AD10D3Q34608680-134C36E5-9FE7-405F-85AA-C2C16BF48671Q35057135-061331ED-CA39-47EF-92C2-AE4B4281E885Q35261122-03050DEE-4AE6-4043-9D60-4D9542B256CDQ35676294-9FA3BFF5-8635-4C3D-867D-B54E908FF0ECQ35722144-1E94CB50-DE07-497B-84CA-B1BC71ED7994Q35763419-6BA0FE4F-AFE9-438D-A081-84250B106E7BQ35798996-9231DFBC-FA97-4ED6-9B0A-C55BFC8F029BQ35810977-7D113CFF-5BB8-4DA6-914A-F71EDB0533D3Q35822301-97836BD1-7E56-4810-972E-7988380F129AQ35924750-C011DE54-BE97-44B4-910C-7FF9FFCAF69BQ36000519-76C4CD8A-C253-457F-BDBF-45AA69B1CE90
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gennaro Ciliberto
@ast
Gennaro Ciliberto
@en
Gennaro Ciliberto
@es
Gennaro Ciliberto
@sl
type
label
Gennaro Ciliberto
@ast
Gennaro Ciliberto
@en
Gennaro Ciliberto
@es
Gennaro Ciliberto
@sl
prefLabel
Gennaro Ciliberto
@ast
Gennaro Ciliberto
@en
Gennaro Ciliberto
@es
Gennaro Ciliberto
@sl
P1053
J-4131-2017
P106
P1153
55368402800
P21
P31
P3829
P496
0000-0003-2851-8605